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787 Right ventricular targeted gene transfer of a -adrenergic receptor kinase
inhibitor improves ventricular performance after pulmonary artery banding
Sitaram M. Emani, MD, Ashish S. Shah, MD, Michael K. Bowman, MD, David C. White, MD,
Sitaramesh Emani, BS, Donald D. Glower, MD, and Walter J. Koch, PhD, Durham, NC
Pretreatment of the right ventricle with ARKct expression was found to have a significant
positive effect on right ventricular contractility, remodeling, and survival 7 days after
pulmonary artery banding. Therefore inhibition of ARK1 can preserve ventricular function in
conditions of increased right ventricular afterload.
794 Adenosine and lidocaine: A new concept in nondepolarizing surgical
myocardial arrest, protection, and preservation
Geoffrey P. Dobson, PhD, and Michael W. Jones, BSc, Townsville, Queensland, Australia
A new nondepolarizing cardioplegic solution employing adenosine and lidocaine arrested rat
hearts for up to 4 hours with 70% to 80% recovery of the cardiac output; 85% to 100%
recovery of heart rate, systolic pressure, and rate-pressure product; and 70% to 80% of baseline
coronary flows. Only 14% of hearts arrested with St Thomas’ Hospital solution no. 2 survived
after 4 hours.
806 Mitogen-activated protein kinase pathways and cardiac surgery
Tanveer A. Khan, MD, Cesario Bianchi, MD, PhD, Marc Ruel, MD, MPH, Pierre Voisine, MD,
and Frank W. Sellke, MD, Boston, Mass
Mitogen-activated protein kinases (MAPK) are involved in vascular permeability, cytokine
production, vasomotor function, and reperfusion injury. Recent studies suggest that myocardial
MAPK potentially mediate detrimental effects of cardioplegia and CPB in humans. In this
review, MAPK pathway characteristics and their role in pathophysiologic responses to cardiac
surgery will be discussed.
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812 The Impella Recover microaxial left ventricular assist device reduces
mortality for postcardiotomy failure: A three-center experience
M. P. Siegenthaler, MD, K. Brehm, MS, T. Strecker, MD, T. Hanke, MD, A. No¨tzold, MD,
M. Olschewski, MSc, M. Weyand, MD, H. Sievers, MD, and F. Beyersdorf, MD, Freiburg,
Lu¨beck, and Erlangen-Nu¨rnberg, Germany
We evaluated patient outcomes and complications associated with the Impella Recover
microaxial device and its effect on survival in patients with postcardiotomy low-output
syndrome. A total of 24 Impella patients and 198 IABP patients were analyzed. Residual
cardiac function of 1 L/min or more was the strongest predictor of survival in Impella patients,
with a survival of 90%, which was significantly higher than in high-risk IABP patients.
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